Brokers Issue Forecasts for Cardiovascular Systems Inc’s Q4 2018 Earnings (CSII)
Cardiovascular Systems Inc (NASDAQ:CSII) – Analysts at Leerink Swann cut their Q4 2018 earnings per share estimates for Cardiovascular Systems in a research note issued on Wednesday. Leerink Swann analyst D. Antalffy now forecasts that the medical device company will post earnings of $0.01 per share for the quarter, down from their prior estimate of $0.05. Leerink Swann has a “Outperform” rating and a $30.00 price objective on the stock. Leerink Swann also issued estimates for Cardiovascular Systems’ Q3 2019 earnings at $0.03 EPS, Q4 2019 earnings at $0.06 EPS and FY2021 earnings at $0.42 EPS.
Other analysts also recently issued reports about the company. Zacks Investment Research upgraded Cardiovascular Systems from a “hold” rating to a “buy” rating and set a $28.00 target price for the company in a research report on Friday. William Blair restated a “market perform” rating on shares of Cardiovascular Systems in a research note on Thursday, December 21st. ValuEngine lowered Cardiovascular Systems from a “hold” rating to a “sell” rating in a research note on Friday, February 2nd. BidaskClub upgraded Cardiovascular Systems from a “sell” rating to a “hold” rating in a research note on Friday, January 26th. Finally, Needham & Company LLC restated a “buy” rating and set a $36.00 price target (down previously from $37.00) on shares of Cardiovascular Systems in a research note on Thursday, October 26th. Three investment analysts have rated the stock with a sell rating, four have issued a hold rating and two have issued a buy rating to the company. Cardiovascular Systems currently has a consensus rating of “Hold” and an average target price of $27.00.
Cardiovascular Systems (NASDAQ:CSII) last released its earnings results on Wednesday, February 7th. The medical device company reported ($0.01) earnings per share for the quarter, topping the consensus estimate of ($0.04) by $0.03. Cardiovascular Systems had a negative return on equity of 0.51% and a negative net margin of 1.62%. The business had revenue of $52.63 million during the quarter, compared to the consensus estimate of $53.39 million. During the same period last year, the company earned $0.03 earnings per share. The business’s revenue for the quarter was up 5.2% compared to the same quarter last year.
Hedge funds have recently modified their holdings of the company. BlueCrest Capital Management Ltd purchased a new stake in shares of Cardiovascular Systems during the second quarter worth about $204,000. Advisor Group Inc. grew its stake in shares of Cardiovascular Systems by 0.4% during the second quarter. Advisor Group Inc. now owns 8,165 shares of the medical device company’s stock worth $263,000 after acquiring an additional 35 shares during the last quarter. JPMorgan Chase & Co. grew its stake in shares of Cardiovascular Systems by 34.5% during the second quarter. JPMorgan Chase & Co. now owns 8,239 shares of the medical device company’s stock worth $265,000 after acquiring an additional 2,115 shares during the last quarter. Teacher Retirement System of Texas purchased a new stake in shares of Cardiovascular Systems during the fourth quarter worth about $273,000. Finally, Trexquant Investment LP purchased a new stake in shares of Cardiovascular Systems during the third quarter worth about $276,000. Institutional investors and hedge funds own 75.29% of the company’s stock.
WARNING: “Brokers Issue Forecasts for Cardiovascular Systems Inc’s Q4 2018 Earnings (CSII)” was first posted by Daily Political and is the property of of Daily Political. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this news story can be read at https://www.dailypolitical.com/2018/02/10/brokers-issue-forecasts-for-cardiovascular-systems-incs-q4-2018-earnings-csii.html.
Cardiovascular Systems Company Profile
Cardiovascular Systems, Inc is a medical technology company. The Company is engaged in treating patients suffering from peripheral and coronary artery diseases, including those with arterial calcium. The Company develops an orbital atherectomy technology for both peripheral and coronary commercial applications.
Receive News & Ratings for Cardiovascular Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiovascular Systems and related companies with MarketBeat.com's FREE daily email newsletter.